FDA Grants Priority Review for Spesolimab | BI US
Read more about Spesolimab, which has been approved by the FDA as a treatment option for generalized pustular psoriasis (GPP) flares in adults.
Search
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
BI Launches Bovikalc Dry for Dairy Cows | Boehringer Ingelheim US
Click here to read more on the launch of the new Bovikalc® Dry for Dairy Cows, an oral mineral supplement contributing to well-being for dairy cows.
BI Cares Signature Program: Empowering Patients to Make Healthy Lifestyle Changes
Signature Program
BI Awards Showcase Veterinary Talent | Boehringer Ingelheim US
Click here to read more on the Boehringer Ingelheim annual awards showcasing and celebrating emerging veterinary talent across the USA.
FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US
FDA approves labeling for Stiolto® Respimat® (tiotropium bromide & olodaterol) with data showing reduction in COPD exacerbations. View ISI, PI & Med Guide.
Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US
Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.
Our Biotherapeutic Technology Partnering Interests
Our Biotherapeutic Technology Partnering Interests
BI Launches Vaccine to Protect Poultry | Boehringer Ingelheim US
Read more on the Boehringer Ingelheim launched Animal Health vaccine, aimed at protecting poultry from three different diseases.
Transition to renewable energy signals a broader commitment to environmental sustainability
Transition to renewable energy signals a broader commitment to environmental sustainability
Partnering in Biotherapeutics Technologies
Our goal of transforming DLL3-positive carcinomas
Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.
New Platform: Unbridle Your Potential | Boehringer Ingelheim US
Read more on the Boehringer Ingelheim brand platform: Unbridle Your Potential, aimed at providing support and leadership for the equine industry.
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Business Resource Groups at Boehringer Ingelheim
Business Resource Groups at Boehringer Ingelheim contribute to and help shape our company culture.
Pharmacy Rotations
Click here to read testimonies from our employees who enrolled in our pharmacy rotations academic program.
HBA Rising Star & Luminary Awards | Boehringer Ingelheim US
Read more on the HBA, is a global nonprofit organization recognizing outstanding individuals and companies who impact and influence women in healthcare.
Clinical Development and Operations
Click here to find out more on how Boehringer Ingelheim is proud to offer a new 2-year Fellowship program within Clinical Operations.
Boehringer Ingelheim to unveil oncology research at WCLC
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH
Shelter Revamps Make for Strong Bonds, More Adoptions
Shelter Revamps Make for Strong Bonds, More Adoptions
Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office
Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office
Management Rotation
Click here to read testimonies from our employees who enrolled in our management rotation program.
Top-line Phase II Data for treatment of MASH
Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).
Six creative Connecticut students turn aspiring ideas into inventive innovation
Learn about the 2023 Connecticut Invention Convention winners.